Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy. PATIENTS AND METHODS: The s...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dahut, William L., Madan, Ravi A., Karakunnel, Joyson J., Adelberg, David, Gulley, James L., Turkbey, Ismail B., Chau, Cindy H., Spencer, Shawn D., Mulquin, Marcia, Wright, John, Parnes, Howard L., Steinberg, Seth M., Choyke, Peter L., Figg, William D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660464/
https://ncbi.nlm.nih.gov/pubmed/23419134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2012.11667.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak